Mais um estudo observacional sugere que rivaroxabam está associado com taxas mais altas de sangramento gastrintestinal do que outros anticoagulantes orais diretos (DOACs).

Rivaroxaban Is Associated with Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants: A Nationwide Propensity Score–Weighted Study – Annals of Internal Medicine (link para o resumo – $ para o texto completo)

Comentário: Rivaroxaban Again Linked to More Bleeding vs Other DOACs – TCTMD

Conteúdo relacionado: Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study – Gastroenterology

Comentário no Twitter

A new study from @uni_iceland and @Landspitali finds that #Rivaroxaban is associated with a higher risk of GI bleeding compared to other direct oral anticoagulants. https://t.co/2J451CN5dD #afib #bleedingrisk #DOAC pic.twitter.com/Q6VSv5Taqg

— Annals of Int Med (@AnnalsofIM) October 13, 2021